Adele Gulfo

Ms. Adele M.
Gulfo is an Independent Non-Executive Director at NewAmsterdam Pharma Co. NV, an Independent Director at Tyra Biosciences, Inc., an Independent Director at Enpro, Inc., a Board of Advisor at 1843 Capital LLC and a Member-Innovation Growth Board at Mass General Brigham, Inc. She is on the Board of Directors at NewAmsterdam Pharma Co. NV, Tyra Biosciences, Inc. and Enpro, Inc. Ms. Gulfo was previously employed as a Chief Executive Officer-Biopharma Commercial Unit by Sumitomo Pharma America, Inc., a Chief Business & Commercial Development Officer by Sumitovant Biopharma, Inc., an Independent Director by Medexus Pharmaceuticals, Inc., a Chief Commercial Development Officer by Roivant Sciences Ltd., an Independent Director by Bemis Co., Inc., an EVP-Global Collaboration & Strategic Operations by Mylan, Inc., an Executive VP & Head-Global Commercial Development by Mylan NV, a President & General Manager by Pfizer Inc., and a Vice President by AstraZeneca PLC.
She also served on the board at Myovant Sciences Ltd., The Committee of 200 and Volunteers of America, Inc. She received her undergraduate degree from Seton Hall University, a graduate degree from the University of Medicine & Dentistry of New Jersey and an MBA from Fairleigh Dickinson University.